Intravenous clevidipine for management of hypertension
Alma Rivera1, Elsa Montoya, Joseph Varon
1Universidad Autónoma de Chihuahua, Chihuahua, México;
Insights
Clevidipine, a fast-acting calcium channel blocker, offers a new option for managing acute hypertension, especially in patients with liver or kidney issues. Its rapid action and safe profile make it valuable for urgent blood pressure control.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
Background:
- Hypertension is a leading global cause of mortality.
- Current treatments often fail, necessitating new antihypertensive agents.
- Limited options exist for rapid blood pressure reduction in hypertensive crises.
Purpose of the Study:
- To review the characteristics of clevidipine.
- To evaluate clevidipine's role in acute hypertension management.
Main Methods:
- Literature review of clevidipine's pharmacological properties.
- Analysis of clinical data regarding its efficacy and safety.
Main Results:
- Clevidipine is a vasculoselective dihydropyridine calcium channel blocker.
- It exhibits a rapid onset and offset of action.
- Metabolism is independent of liver and kidney function, allowing use in patients with dysfunction.
Conclusions:
- Clevidipine is effective for rapid blood pressure reduction when oral therapy is unsuitable.
- Its use is beneficial in the perioperative setting.
- Clevidipine presents a valuable option for managing acute hypertension.
Abstract:
Hypertension remains one of the most prevalent diseases affecting our society, and its complications lead the list of causes of mortality all over the world. Most efforts to control the disease are unsuccessful, failing in at least two-thirds of affected patients, despite the availability of multiple drugs for its treatment. The limited number of medications available for aggressive management of hypertensive crises has intensified the search for novel drugs that can achieve a rapid decrease in blood pressure without increasing the possible complications. Clevidipine is a novel, vasculoselective, dihydropyridine calcium channel blocker characterized by a very fast onset and offset of action. Metabolism of clevidipine does not occur in the liver or kidneys, and thus there are no restrictions to using clevidipine in patients with hepatic or renal dysfunction. This agent has been widely used to reduce blood pressure when oral therapy is not appropriate, and its use in the perioperative setting has been shown to be beneficial. This manuscript reviews the key characteristics of clevidipine and its role in the management of acute hypertension.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Hypertension V: Nursing Management
Venous Thrombosis IV: Nursing Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Continuous Renal Replacement Therapy
